Analyst Ratings for Biogen
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 33 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. The average price target is $332.03, implying an upside from the current price of $266.365. This represents a 2.15% decrease from the previous average price target of $339.32.
August 29, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given an average price target of $332.03 for Biogen, implying an upside from the current price.
The average price target given by analysts suggests a potential upside for Biogen's stock. This could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100